Pancreatic head cancer represents one of the most frequent malignancies with an incidence of about 13500 new cases each year. The primary objective of the study is to test whether there are bacterial species associated with increased risk of complications in patients with peri-ampullary neoplasia undergoing DCP.
Age ≥18 years
Diagnosis of resectable pancreatic adenocarcinoma with indication for "upfront" surgical treatment
ASA (American Society of Anesthesiology) score < 4
Obtaining informed consent
None
Single group
Microbiota analysis
Diagnostic testUpon acquisition of informed consent, fecal, digiunal mucosa, biliary and pancreatic fluid samples will be collected for microbiota analysis
Structure of the gut microbiome
The structure of the gut microbiome will be characterized on the samples by "next-generation sequencing" of the hypervariable region V3 to V4 of the 16S rRNA gene (bacterial component) and by "shotgun genomics"; ecosystem functionality will be assessed by measuring the fecal concentration of short-chain fatty acids (SCFA).
Click on the lead sponsor to view all of their trials.
